If Remicade Biosimilar Hits The U.S. Market In 2017, Does J&J Face Any Meaningful EPS Decline?
Remicade U.S. Approval In 2017 Will Not Have Meaningful Impact On J&J’s 2017 EPS (~ -2% Impact)
Have more questions about Johnson & Johnson? See the links below.
- Drugs, Devices, Consumer: What’s Johnson & Johnson’s Revenue and Earnings breakdown?
- What’s J&J’s Fundamental Value Based On Expected 2015 Results?
- How Increased Focus On Pharmaceuticals In The Last 5 Years Has Helped J&J?
- By How Much Can J&J’s Revenue And EBITDA Grow Over The Next 3 Years?
- What’s J&J’s Fundamental Value Based On Expected 2015 Results?
- How Much Revenues Can J&J’s Phase 3 Pipeline Add By 2020?
- What Percentage Of Its Revenue Could J&J Lose Solely Due To Patent Losses Over The Next 5 Years?
- Considering Recent Divestitures, Should J&J Trim Its Medical Devices Segment Further?
Relevant Articles
- Which Is A Better Pick: JNJ Stock Or ABBV Stock?
- Should You Pick JNJ Stock After An Upbeat Q3?
- What To Expect From Johnson & Johnson’s Q3?
- Is Disney A Better Pick From The Dow Jones Index Over Johnson & Johnson Stock ?
- Johnson & Johnson Poised To Do Well, But Are These Steady Eddie Stocks Better Bets?
- JNJ Stock A Winner Right Now?
Notes:
1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our complete analysis for Johnson & Johnson
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)